|
gptkbp:instance_of
|
gptkb:DNA
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Andexanet_alfa
|
|
gptkbp:clinical_trial
|
Phase 3
ANNEXA-4
ANNEXA-4 Extension Study
effective in reversing anticoagulation
|
|
gptkbp:clinical_use
|
emergency situations
|
|
gptkbp:community_health
|
training on administration
|
|
gptkbp:competitors
|
other reversal agents
|
|
gptkbp:contraindication
|
known hypersensitivity to andexanet alfa
|
|
gptkbp:cost_effectiveness
|
under evaluation
|
|
gptkbp:dosage_form
|
lyophilized powder
|
|
gptkbp:dosing_adjustment
|
based on weight
|
|
gptkbp:drug_interactions
|
anticoagulants
antiplatelet agents
|
|
gptkbp:duration
|
as needed
|
|
gptkbp:formulation
|
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Andexxa
|
|
gptkbp:indication
|
apixaban reversal
rivaroxaban reversal
|
|
gptkbp:ingredients
|
gptkb:andexanet_alfa
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
gptkb:American_Heart_Association
gptkb:European_Society_of_Cardiology
gptkb:American_College_of_Cardiology
|
|
gptkbp:manufacturer
|
gptkb:Portola_Pharmaceuticals
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:2018
|
|
gptkbp:mechanism_of_action
|
binds to factor Xa
|
|
gptkbp:monitoring_requirement
|
coagulation parameters
|
|
gptkbp:patient_education
|
importance of monitoring
|
|
gptkbp:patient_outcome
|
reduced bleeding complications
|
|
gptkbp:patient_population
|
patients on anticoagulants
|
|
gptkbp:pharmacokinetics
|
rapid onset of action
reverses anticoagulant effects
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
included in treatment protocols
|
|
gptkbp:regulatory_compliance
|
granted in 2018
|
|
gptkbp:related_products
|
gptkb:rivaroxaban
gptkb:apixaban
gptkb:dabigatran
gptkb:edoxaban
|
|
gptkbp:research
|
ongoing studies for efficacy
long-term safety studies
|
|
gptkbp:research_focus
|
anticoagulation reversal
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
single dose
|
|
gptkbp:side_effect
|
thromboembolic events
severe allergic reactions
hypersensitivity reactions
thrombotic events
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:treatment
|
improved hemostasis
|
|
gptkbp:used_for
|
reversal of anticoagulation
|
|
gptkbp:bfsParent
|
gptkb:Portola_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|